Full-Time

Area Business Lead

Central Nervous System

Updated on 7/21/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$157.7k - $235.8k/yr

+ Incentive Opportunity

Columbus, OH, USA

In Person

Must reside within 50 miles of Columbus, Ohio.

Category
Business & Strategy (1)
Required Skills
Market Research
Data Analysis

Get referred to Otsuka Pharmaceutical

Find people who can refer or advise you

Requirements
  • Bachelor’s degree.
  • Previous experience leading account managers or alliance/partnership managers, including developing and implementing account plans, contracting for various health ecosystem players (e.g., health system or hospital).
  • Must reside within a commutable distance of 50 miles from the primary city in the sales territory (Columbus, OH).
  • Ability to travel is required
Responsibilities
  • Collaborate with the ecosystem cross-functional team to develop and execute the ecosystem strategy to enhance customer satisfaction, improve patient outcomes, and create business opportunities for Otsuka.
  • Develop and drive the ecosystem commercial strategy.
  • Lead a team of Neuroscience Specialists within an ecosystem to drive appropriate clinical demand and improve patient and customer experiences.
  • Execute and adapt the regional/ecosystem plan to achieve patient-centric objectives, KPIs, and performance targets.
  • Continuously scan the industry and broader commercial environment to identify best practices in the healthcare ecosystem and integrate them into Otsuka through innovative account management processes.
  • Consolidate insights gathered from the field force and other sources (e.g., analytics) to inform regional business plans.
  • Coach Neuroscience Specialists to shape customer plans based on market dynamics to address customer needs and deliver performance against Neuroscience Specialists and ecosystem KPIs.
  • Collaborate with ecosystem partners to develop and execute customer engagement strategies and initiatives, gaining insights and perspectives through strong external customer interaction, primary and secondary market research, and field organization.
  • Build, maintain, and leverage networks and relationships in the complex healthcare ecosystem to gain insight into customer needs and priorities and contribute to improved customer, patient, and business outcomes.
  • Partner with senior customers (e.g., leaders in IDNs) within the ecosystem by improving and maintaining ongoing relationships and establishing patient-centric platforms for strategic partnership.
  • Understand the unique needs of each customer in their pursuit of improved patient outcomes, lower costs, and improved quality of care by building, maintaining, and leveraging networks and relationships in the healthcare ecosystem and co-creating solutions with customers.
  • Collaborate across ecosystem roles in support of shared patient-centric and customer engagement quality goals, including customizing local field deployment based on local needs and developing ecosystem strategic plans and KPIs.
  • Integrate, synthesize, and harness knowledge from established relationships to develop a deep understanding of the ecosystem and effectively influence the system to deliver improved patient outcomes.
  • Conduct business to the highest ethical and professional standards, consistent with Otsuka guidelines and policies, ensuring compliance with regulatory standards in all communications and activities.
  • Drive a high-performance, patient-centric, highly engaged culture within the ecosystem.
  • Create and foster a culture that is collaborative and customer-centric to ensure solutions are designed to continuously enhance customer engagement, satisfaction, and improved patient outcomes.
  • Provide adaptive leadership and coaching to the team to support, motivate, and enable them to successfully deliver the business plan and priorities.
  • Ensure that the sales goals and forecasts for the region are consistent with the organization’s long-range strategic objectives.
  • Lead business analysis to identify and recommend strategic opportunities to maximize business results, incorporating input and ideas from across Otsuka.
  • Track the ecosystem customer experience, both formally and informally, and use this information to enhance customer engagement and strategy.
  • Foster a cross-functional account environment that is collaborative and customer-centric to engage the customer as solution partners across the portfolio.
Desired Qualifications
  • MBA or other related graduate degree preferred.
  • Previous cross-functional industry experience in commercial life sciences (pharma or biotechnology) or related industry engaging with key healthcare ecosystem players (e.g., payers, health systems) is a plus.
  • Ability to work in an ambiguous environment undergoing transformation is a strong plus.
  • Proven track record in coaching, training, and/or mentoring peers or others as assigned; helping such others to better meet or exceed their goals, targets, and other responsibilities.
  • Proven track record for consistently meeting or exceeding financial and/or other quantitative targets, as well as qualitative goals.
  • Demonstration of in-depth knowledge of strategy development, including contracting strategy, administration, and pull-through is a strong plus.
  • Previous field sales management and/or marketing experience in the Neuroscience or Nephrology market, or related industry is preferred.
  • Strong understanding of healthcare compliance, legal, and regulatory landscape.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 4D-150 Phase 3 data showed sustained efficacy and strong APAC commercialization potential.
  • VOYXACT advances Otsuka’s nephrology franchise with accelerated U.S. approval and confirmatory readouts.
  • Japan reimbursement for Paradise renal denervation supports a new resistant-hypertension market entry.

What critics are saying

  • 4D-150 requires successful Phase 3 outcomes before Otsuka monetizes its APAC rights.
  • Accelerated approval leaves VOYXACT exposed to confirmatory-trial failure and withdrawal risk.
  • Device and digital hypertension products face slow physician adoption and reimbursement friction in Japan.

What makes Otsuka Pharmaceutical unique

  • Otsuka combines psychiatry, rare disease, and device distribution under one global platform.
  • Its 4D-150 Asia-Pacific license extends gene therapy reach into retinal vascular diseases.
  • Otsuka pairs internal development with external licensing across Japan, China, Australia, and Oceania.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
SonoThera, Inc.
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.